Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-BTC01 in HER2-expressing advanced biliary tract cancer
jRCT2031240225Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Randomised trial of trastuzumab deruxtecan, rilvegostomig, gemcitabine, cisplatin and durvalumab in biliary cancer and biliary adenocarcinoma (4 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability in the safety run-in and Overall survival. Started Jun 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecanrilvegostomiggemcitabinecisplatindurvalumab
03
Conditions
biliary cancerbiliary adenocarcinoma
Beyond the preview
Go deeper on jRCT2031240225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240225.